Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-immunization of COVID-19, Influenza, and Pneumococcal Vaccines
NCT05298800Phase 4Unknown
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19), influenza and pneumococcal disease (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Seroconversion rate of neutralizing antibody at 28 days. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)influenzapneumococcal disease
Beyond the preview
Go deeper on NCT05298800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298800.